Sai Life Sciences, Laurus Labs Share Price Hit Record Highs; Stocks Surge Up to 40% in 6 Months

Shares of contract development and manufacturing organisation (CDMO) companies Sai Life Sciences and Laurus Labs touched fresh all-time highs during intraday trading on June 5, outperforming the broader market.

Sai Life Sciences rose about 2% to ₹1,187.65, while Laurus Labs gained around 1% to ₹1,449.90. In comparison, the BSE Sensex remained largely flat during the session.

Returns Over the Last 6 Months

Both stocks have delivered impressive gains despite weakness in the broader market.

Sai Life Sciences Maintains Strong Growth Outlook

Sai Life Sciences' management has reiterated its long-term guidance of 15–20% revenue CAGR and 28–30% EBITDA margins over the next 2 to 3 years.

The company expects growth to be supported by:

• A diversified late-stage drug development pipeline
• Commercialisation of internally developed molecules
• Expansion into peptides, oligonucleotides and antibody-drug conjugates (ADCs)
• Ongoing investments in manufacturing capacity 

Management also highlighted opportunities arising from global pharmaceutical companies diversifying supply chains away from China and increasing outsourcing to Indian CDMO firms.

Laurus Labs Benefits From CDMO Expansion

Laurus Labs also reported strong momentum in its CDMO business during the March 2026 quarter.

Its synthesis and CDMO segment recorded:

• 14% year-on-year revenue growth
• 28% quarter-on-quarter revenue growth 

The growth was driven by increasing commercialisation of late-stage projects and higher supplies of new chemical entity (NCE) APIs.

Laurus Labs Targets CDMO-Led Growth

The company is expanding into peptides and fermentation technologies while broadening its customer base across global markets.

Laurus Labs aims to increase the contribution of its CDMO business to 50% of total revenue by FY29.

Growth drivers include:

• Recovery in the generics business
• Higher manufacturing utilisation
• Oncology API expansion
• Increased order inflows from global pharmaceutical companies
• Commercialisation of new projects 

Conclusion

Sai Life Sciences and Laurus Labs continue to attract investor interest as demand for outsourced pharmaceutical research and manufacturing services grows globally. Strong order pipelines, capacity expansion plans and increasing CDMO contributions have helped both companies outperform the broader market, pushing their shares to record highs and delivering gains of up to 40% over the past 6 months.

Want to track these market movements in Hindi? Visit Angel One News for daily updates and comprehensive share market news in Hindi.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.